Gastric cancer indication for Herceptin

Herceptin 150mg vial: medicine used to treat breast cancer
Herceptin 150mg vial: medicine used to treat breast cancer

The breast cancer treatment Herceptin (trastuzumab) has been approved for the treatment of HER2-positive gastric cancer.

It is indicated as first-line therapy, in combination with capecitabine (or 5-FU) and cisplatin, for metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.

The licence extension is based on results of the ToGA (Trastuzumab for GAstric Cancer) trial, which enrolled 594 patients with inoperable locally advanced, recurrent and/or metastatic HER2-positive gastric cancer.

In this trial, trastuzumab plus chemotherapy increased median survival time from 11.8 months with chemotherapy alone to 16 months-representing a 35% increase in overall survival.

Trastuzumab suppresses tumour growth by specifically targeting the HER2 receptor, and should only be used in patients whose tumours have HER2 overexpression as defined on the SPC. HER2 is overexpressed in around 20% of gastric cancers.

View Herceptin drug record

Further information: Roche

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more